$337M | ||
$259M | ||
$79M | ||
$76M | ||
$60M | ||
$57M |
Buys | $53,141 | 1 | 4 |
Sells | $7,108,568 | 26 | 96 |
SEMEDO ANTHONY B. | director | 1 | $53,141 | 1 | $242,628 | $-189,487 |
Berry Lance A | Executive VP, CFO | 0 | $0 | 2 | $210,754 | $-210,754 |
GREEN ANDREW M | VP Regulatory | 0 | $0 | 1 | $228,540 | $-228,540 |
Getz Matthew A | VP, Human Resources | 0 | $0 | 1 | $238,434 | $-238,434 |
Stanton Marshall S. | SVP, Clinical & MD Affair | 0 | $0 | 3 | $475,010 | $-475,010 |
Horton Amy | VP, Chief Accounting Officer | 0 | $0 | 4 | $570,699 | $-570,699 |
Davis John E | Chief Commercial Officer | 0 | $0 | 4 | $675,515 | $-675,515 |
Holloway Jean F | SVP, General Counsel | 0 | $0 | 8 | $1.13M | $-1.13M |
Mackin James P | President & CEO | 0 | $0 | 2 | $3.34M | $-3.34M |
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.
Over the last 12 months, insiders at Artivion, Inc. have bought $53,141 and sold $7.11M worth of Artivion, Inc. stock.
On average, over the past 5 years, insiders at Artivion, Inc. have bought $260,731 and sold $4.01M worth of stock each year.
Highest buying activity among insiders over the last 12 months: SEMEDO ANTHONY B. (director) — $53,141.
The last purchase of 2,100 shares for transaction amount of $53,141 was made by SEMEDO ANTHONY B. (director) on 2025‑03‑05.
2025-05-09 | Sale | Stanton Marshall S. | SVP, Clinical & MD Affair | 10,548 0.0249% | $29.13 | $307,265 | +1.05% | |
2025-03-11 | Sale | Davis John E | Chief Commercial Officer | 15,100 0.0361% | $23.61 | $356,549 | +2.56% | |
2025-03-11 | Sale | Holloway Jean F | SVP, General Counsel | 18,020 0.0431% | $23.61 | $425,510 | +2.56% | |
2025-03-06 | Sale | Mackin James P | President & CEO | 88,439 0.2108% | $24.77 | $2.19M | -2.62% | |
2025-03-06 | Sale | Davis John E | Chief Commercial Officer | 2,618 0.0062% | $24.80 | $64,939 | -2.62% | |
2025-03-06 | Sale | Holloway Jean F | SVP, General Counsel | 2,124 0.0051% | $24.80 | $52,685 | -2.62% | |
2025-03-06 | Sale | Berry Lance A | Executive VP, CFO | 4,909 0.0117% | $24.80 | $121,764 | -2.62% | |
2025-03-06 | Sale | Horton Amy | VP, Chief Accounting Officer | 1,048 0.0025% | $24.80 | $25,995 | -2.62% | |
2025-03-06 | Sale | Stanton Marshall S. | SVP, Clinical & MD Affair | 1,603 0.0038% | $24.80 | $39,761 | -2.62% | |
2025-03-05 | Sale | Holloway Jean F | SVP, General Counsel | 472 0.0011% | $25.29 | $11,935 | -5.08% | |
2025-03-05 | SEMEDO ANTHONY B. | director | 2,100 0.0049% | $25.30 | $53,141 | -5.08% | ||
2025-02-24 | Sale | Mackin James P | President & CEO | 42,156 0.0972% | $27.31 | $1.15M | -13.21% | |
2025-02-24 | Sale | Davis John E | Chief Commercial Officer | 2,846 0.0066% | $27.31 | $77,713 | -13.21% | |
2025-02-24 | Sale | Davis John E | Chief Commercial Officer | 6,457 0.0149% | $27.31 | $176,315 | -13.21% | |
2025-02-24 | Sale | Holloway Jean F | SVP, General Counsel | 3,685 0.0085% | $27.31 | $100,623 | -13.21% | |
2025-02-24 | Sale | Holloway Jean F | SVP, General Counsel | 5,335 0.0123% | $27.31 | $145,678 | -13.21% | |
2025-02-24 | Sale | Horton Amy | VP, Chief Accounting Officer | 3,323 0.0077% | $27.31 | $90,738 | -13.21% | |
2025-02-24 | Sale | Stanton Marshall S. | SVP, Clinical & MD Affair | 4,687 0.0108% | $27.31 | $127,983 | -13.21% | |
2025-02-24 | Sale | Berry Lance A | Executive VP, CFO | 3,259 0.0075% | $27.31 | $88,990 | -13.21% | |
2024-12-11 | Sale | Holloway Jean F | SVP, General Counsel | 8,070 0.0194% | $30.13 | $243,109 | -6.94% |
Mackin James P | President & CEO | 860368 2.0148% | $25.39M | 4 | 18 | +33.26% |
Davis John E | Chief Commercial Officer | 208778 0.4889% | $6.16M | 2 | 20 | +28.47% |
Holloway Jean F | SVP, General Counsel | 197184 0.4618% | $5.82M | 0 | 29 | |
Berry Lance A | Executive VP, CFO | 153431 0.3593% | $4.53M | 0 | 2 | |
Horton Amy | VP, Chief Accounting Officer | 146651 0.3434% | $4.33M | 0 | 28 | |
Stanton Marshall S. | SVP, Clinical & MD Affair | 105332 0.2467% | $3.11M | 0 | 10 | |
SEMEDO ANTHONY B. | director | 35659 0.0835% | $1.05M | 2 | 1 | +9.19% |
Getz Matthew A | VP, Human Resources | 34116 0.0799% | $1.01M | 0 | 9 | |
GREEN ANDREW M | VP Regulatory | 33503 0.0785% | $988,673.53 | 0 | 8 | |
ANDERSON STEVEN G | Executive Chairman | 1300676 3.0459% | $38.38M | 0 | 9 | |
LEE DAVID ASHLEY | Executive VP, COO & CFO | 347217 0.8131% | $10.25M | 2 | 19 | +25.04% |
Capps Scott B | VP, Clinical Research | 148640 0.3481% | $4.39M | 0 | 5 | |
McCall Ronald D | director | 121768 0.2852% | $3.59M | 0 | 22 | |
FRONK DAVID | VP Reg. Affrs. and Qual Assur. | 101528 0.2378% | $3M | 0 | 1 | |
Burris Jeffrey W | Vice President & Gen. Counsel | 93576 0.2191% | $2.76M | 0 | 5 | |
Gale David C | VP, Research & Development | 77135 0.1806% | $2.28M | 0 | 2 | |
SEERY GERALD B | Sr. VP, Sales and Marketing | 71999 0.1686% | $2.12M | 0 | 1 | |
RONALD C ELKINS | director | 64843 0.1518% | $1.91M | 0 | 21 | |
Benson James | director | 54086 0.1267% | $1.6M | 0 | 5 | |
Maney Rochelle L. | VP, Quality | 46569 0.1091% | $1.37M | 0 | 8 | |
Maier Dennis B | SVP, Operations | 34724 0.0813% | $1.02M | 0 | 8 | |
Anderson Bruce G. | VP, US Sales &Global Marketing | 34564 0.0809% | $1.02M | 0 | 6 | |
Bullock James | director | 34023 0.0797% | $1M | 1 | 0 | +47.76% |
Tyrs Florian | VP, Global Operations | 21558 0.0505% | $636,176.58 | 0 | 3 |
Increased Positions | 74 | +35.58% | 3M | +9.69% |
Decreased Positions | 84 | -40.38% | 1M | -3.92% |
New Positions | 18 | New | 987,505 | New |
Sold Out Positions | 25 | Sold Out | 510,266 | Sold Out |
Total Postitions | 198 | -4.81% | 38M | +5.77% |
Blackrock, Inc. | $144,710.00 | 14.43% | 6.2M | -230,390 | -3.58% | 2025-03-31 |
Vanguard Group Inc | $65,438.00 | 6.52% | 2.8M | +1,771 | +0.06% | 2024-12-31 |
Perceptive Advisors Llc | $65,177.00 | 6.5% | 2.79M | 0 | 0% | 2024-12-31 |
Macquarie Group Ltd | $63,860.00 | 6.37% | 2.74M | -8,997 | -0.33% | 2024-12-31 |
Morgan Stanley | $55,060.00 | 5.49% | 2.36M | -90,519 | -3.69% | 2024-12-31 |
Juniper Investment Company, Llc | $48,950.00 | 4.88% | 2.1M | 0 | 0% | 2024-12-31 |
Wellington Management Group Llp | $38,730.00 | 3.86% | 1.66M | +3,817 | +0.23% | 2024-12-31 |
State Street Corp | $36,061.00 | 3.6% | 1.55M | +30,903 | +2.04% | 2024-12-31 |
Dimensional Fund Advisors Lp | $34,358.00 | 3.43% | 1.47M | -68,849 | -4.47% | 2024-12-31 |
Gw&K Investment Management, Llc | $25,935.00 | 2.59% | 1.11M | -23,816 | -2.1% | 2024-12-31 |